Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study of Brivekimig Followed by a Maintenance Period in Participants With Moderate to Severe Hidradenitis Suppurativa

NCT07170917 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT07170917
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07170917 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Dose-ranging Phase 2 Study of Brivekimig Followed by a Maintenance Period in Participants With Moderate to Severe Hidradenitis Suppurativa
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Recruiting
Start date
November 6, 2025
Completion date
November 23, 2029
Enrollment
208 (estimated)
Sites
85

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa